Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
ARQ 092
DRUG
2 trials
Sponsors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Conditions
Growth Disorders
Malignant Lymphoma
PIK3CA-Related Overgrowth Spectrum (PROS)
Proteus Syndrome
Solid Tumor
Tumor
Phase 1
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Completed
NCT01473095
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Malignant Lymphoma, Solid Tumor, Tumor
Start: 2011-11-30
End: 2017-08-07
Updated: 2017-10-23
Unknown Phase
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
NCT03317366
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Growth Disorders, PIK3CA-Related Overgrowth Spectrum (PROS), Proteus Syndrome
Updated: 2021-08-06